Ind-Swift gets EUDRA GMP certificate from Hungary for Punjab facility
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ind-Swift Laboratories' Global Business Unit formulations facility at Derabassi, Punjab has received a GMP compliance certificate from Hungary's National Center for Public Health and Pharmacy (NNGYK), following an EUDRA GMP inspection in November 2025. The certificate is valid for 3 years and opens access to European and other regulated markets. The facility already holds WHO-GMP, TGA Australia, MHRA UK, SAPRA South Africa, and EU-GMP certifications.
Strengthens regulatory footprint enabling higher-value European exports, potentially supporting revenue growth and margin expansion from regulated markets.